NYSE Amex grants Interleukin Genetics extension for regaining compliance

Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that the Corporate Compliance Staff of the NYSE Amex LLC (the "Exchange") has granted the Company an extension to meet the Exchange's continued listing standards and become compliant.  The Company will remain listed up to June 23, 2010, subject to periodic review by the Exchange staff during the extension period of progress towards the Company's plan to regain compliance.

As previously disclosed, Interleukin Genetics received notice from the Exchange indicating that the Company is not in compliance with Section 1003(a)(i), (ii) or (iii) of the Company Guide.

While the Company is taking steps to regain compliance with all applicable requirements for continued listing on the Exchange by June 23, 2010, there can be no assurance that the company will be able to do so in such time frame, or at all.  

SOURCE Interleukin Genetics, Inc.